Notícias Ocugen Inc - OCGN | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Ocugen Inc (OCGN)
Ocugen Inc (OCGN) Notícias

Ocugen Inc (OCGN)

0,71

-0,005

(-0,70%)

Fechado 18 Janeiro 6:00PM

Atrasado por 15 minutos

0,7126

0,0026

(0,37%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 4 - Statement of changes in beneficial ownership of securities

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 8-K - Current report

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

1
2
3
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições